The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene

Regulatory Toxicology and Pharmacology

Volumn 47, Issue 1, 2007, Pages 1-18

  Covington, Tammie R ^a   Robinan Gentry, P ^a   Van Landingham, Cynthia B ^a   Andersen, Melvin E ^b   Kester, Janet E ^a   Clewell, Harvey J ^a  

^a ENVIRON INTERNATIONAL CORPORATION   (United States)

^b CIIT CENTERS FOR HEALTH RESEARCH   (United States)

Author keywords

Markov chain Monte Carlo; PBPK modeling; Perchloroethylene; Risk assessment

Indexed keywords

TETRACHLOROETHYLENE;

ARTICLE; BLOOD LEVEL; DATA ANALYSIS; ENVIRONMENTAL EXPOSURE; HUMAN; MONTE CARLO METHOD; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; TOXICOKINETICS; URINARY EXCRETION;

CARCINOGENS, ENVIRONMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHALATION EXPOSURE; MALE; MARKOV CHAINS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; PUBLIC HEALTH; RISK ASSESSMENT; TETRACHLOROETHYLENE; UNCERTAINTY;

EID: 33751083612     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2006.06.008     Document Type: Article

References (36)

1. Andersen M.E., Clewell H.J., Gargas M.L., Smith F.A., and Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87 2 (1987) 185-205
2. Astrand P., and Rodahl K. Textbook of Work Physiology (1970), McGraw-Hill, New York
3. Bernillon P., and Bois F. Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environ. Health Perspect. 108 Suppl. 5 (2000) 883-893
4. Bois F. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ. Health Perspect. 108 Suppl .2 (2000) 307-316
5. Bois, F., Maszle, D., Revzan, K., Tillier, S., Yuan, Z., 2002. MCSIM Version 5 beta 2. Available at .
6. Bois F.Y., Gelman A., Jiang J., Maszle D.R., Zeise L., and Alexeef G. Population toxicokinetics of tetrachloroethylene. Arch. Toxicol. 70 6 (1996) 347
7. Bois F.Y., Zeise L., and Tozer T.N. Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats, and humans. Toxicol. Appl. Pharmacol. 102 2 (1990) 300-315
8. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13 4 (1997) 407-484
9. Caldwell D.J. Review of mononuclear cell leukemia in F-344 rat bioassays and its significance to human cancer risk: a case study using alkyl phthalates. Regul. Toxicol. Pharmacol. 30 (1999) 45-53
10. Carlin B., and Louis T. Bayes and Empirical Bayes Methods for Data Analysis (2000), CRC, Boca Raton
11. Chen C.W., and Blancato J.N. Role of pharmacokinetic modeling in risk assessment: perchloroethylene as an example. In: Gillette J., and Jollow D. (Eds). Pharmacokinetics in Risk Assessment. Drinking Water and Health vol. 8 (1987), National Academy Press, Washington, DC 369-390
12. Clewell H.J., and Andersen M.E. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111 (1996) 315-329
13. Clewell H.J., and Andersen M.E. Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene. Crit. Rev. Toxicol. 34 5 (2004) 385-445
14. Clewell H.J., Gentry P.R., Covington T.R., and Gearhart J.M. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ. Health Perspect. 108 Suppl. 2 (2000) 283-305
15. Clewell H.J., Gentry P.R., Gearhart J.M., Allen B.C., and Andersen M.E. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci. Total. Environ. 274 (2001) 37-66
16. Clewell H.J., Gentry P.R., Kester J.E., and Andersen M.E. Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene. Crit. Rev. Toxicol. 35 5 (2005) 413-433
17. Dekant W., Metzler M., and Henschler D. N-acetylcysteine as a urinary metabolite of tetrachloroethylene: bioactivation through glutathione conjugation as a possible explanation of its nephrocarcinogenicity. J. Biochem. Toxicol. 1 2 (1986) 57-72
18. Farrar D., Allen B., Crump K., and Shipp A. Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. Toxicol. Lett. 49 (1989) 371-385
19. Fernandez J., Guberan E., and Caperos J. Experimental human exposures to tetrachloroethylene vapor and elimination in breath after inhalation. Am. Ind. Hyg. Assoc. J. 37 (1976) 143-150
20. Fisher J., Mahle D., and Abbas R. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. Toxicol. Appl. Pharmacol. 152 2 (1998) 339-359
21. Gearhart J.M., Mahle D.A., Greene R.J., Seckel C.S., Flemming C.D., Fisher J.W., and Clewell III H.J. Variability of physiologically-based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE). Toxicol. Lett 68 1-2 (1993) 131-144
22. Gelman A., Bois F., and Jiang J. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J. Am. Stat. Assoc. 91 436 (1996) 1400-1412
23. Hattis D., White P., and Koch P. Uncertainties in pharmacokinetic modeling for perchloroethylene: II. Comparison of model predictions with data for a variety of different parameters. Risk Anal. 13 (1993) 599-610
24. Hattis D., White P., Marmorstein L., and Koch P. Uncertainties in pharmacokinetic modeling for perchloroethylene. I. Comparison of model structure, parameters, and predictions for low-dose metabolism rates for models derived by different authors. Risk Anal. 10 (1990) 449-458
25. Kharasch E.D., Hankins D.C., and Thummel K.E. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 82 3 (1995) 689-699
26. Loizou G.D. The application of physiologically based pharmacokinetic modelling in the analysis of occupational exposure to perchloroethylene. Toxicol. Lett. 124 1-3 (2001) 59-69
27. Monster A., Boersma G., and Steenweg H. Kinetics of tetrachloroethylene in volunteers; influence of exposure concentration and work load. Int. Arch. Occup. Environ Health 42 (1979) 303-309
28. National Center for Health Statistics, 2000. The National Health and Nutrition Examination Survey (NHANES), 1999-2000. Available at .
29. Occupational Safety and Health Administration (OSHA), 1997. Occupational exposure to methylene chloride. Fed. Reg. 62(7), 1493-1619.
30. Office of Environmental Health Hazard Assessment (OEHHA), 2001. Public Health Goal for Tetrachloroethylene in Drinking Water. California Environmental Protection Agency, Oakland, CA.
31. Office of Environmental Health Hazard Assessment (OEHHA), 2003. Process for PHG development and chemicals undergoing evaluation. .
32. Reitz R., Gargas M., Mendrala A., and Schumann A. In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokineticmodeling in rats, mice, and humans. Toxicol. Appl. Pharmacol. 136 (1996) 289-306
33. U.S. Environmental Protection Agency (USEPA), 2000. Toxicological review of vinyl chloride. Washington, DC, EPA-635R-00/004.
34. U.S. Environmental Protection Agency (USEPA), 2003. Guidelines for Carcinogen Risk Assessment. Washington, DC, NCEA-F-0644.
35. Volkel W., Friedewald M., Lederer E., Pahler A., Parker J., and Dekant W. Biotransformation of perchloroethene: dose-dependent excretion of trichloroacetic acid, dichloroacetic acid, and N-acetyl-S-(trichlorovinyl)-l-cysteine in rats and humans after inhalation. Toxicol. Appl. Pharmacol. 153 1 (1998) 20-27
36. Ward R.C., Travis C.C., Hetrick D.M., Andersen M.E., and Gargas M.L. Pharmacokinetics of tetrachloroethylene. Toxicol Appl. Pharmacol. 93 1 (1988) 108-117